임상 한눈에 보기

• 73건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 2, Phase 3 · Phase 3
• Status: No longer available · Active, not recruiting · Recruiting
• 주요 endpoint: Proportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis. · Difference in proportion of patients with inadequate control of inflammation (defined as two or more episodes of raised CRP or faecal calprotectin) treated with conventional therapeutics versus treatment escalation 24 months post UC diagnosis. · Characterise patient demography at the time of diagnosis and associated co-morbidities and extra-intestinal manifestations of interest. · Map treatment use from conventional therapies to advanced therapies from time of UC diagnosis. · Change from Baseline in Faecal Calprotectin (Fcal).
• 등록된 결과: ORR 90%
• 핵심: High skin clearance with infrequent dosing

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.